

Theodore A Gooley

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/6311079/publications.pdf>

Version: 2024-02-01

164
papers

14,757
citations

25034
57
h-index

18647
119
g-index

165
all docs

165
docs citations

165
times ranked

11577
citing authors

#	ARTICLE	IF	CITATIONS
1	90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma. Bone Marrow Transplantation, 2021, 56, 202-209.	2.4	6
2	HbA1c and Glucose Management Indicator Discordance: A Real-World Analysis. Diabetes Technology and Therapeutics, 2021, 23, 253-258.	4.4	47
3	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 632-641.	1.2	21
4	Use of the HLA-B leader to optimize cord blood transplantation. Haematologica, 2021, 106, 3107-3114.	3.5	12
5	EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 553-561.	2.4	70
6	Azithromycin Use and Increased Cancer Risk among Patients with Bronchiolitis Obliterans after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 392-400.	2.0	23
7	Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. Lancet Haematology, the, 2020, 7, e50-e60.	4.6	53
8	Early Post-Transplantation Spirometry Is Associated with the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 943-948.	2.0	19
9	HLA-B Leader and Survivorship after HLA-Mismatched Unrelated Donor Transplantation. Blood, 2020, 136, 362-369.	1.4	20
10	Role of HLA-DP Expression in Graft-Versus-Host Disease After Unrelated Donor Transplantation. Journal of Clinical Oncology, 2020, 38, 2712-2718.	1.6	39
11	A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-Hodgkin lymphoma. American Journal of Hematology, 2020, 95, 775-783.	4.1	7
12	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood, 2019, 133, 1652-1663.	1.4	277
13	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood, 2019, 133, 1876-1887.	1.4	230
14	The β -emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model. Blood, 2019, 134, 1247-1256.	1.4	30
15	A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks. British Journal of Haematology, 2019, 186, 159-162.	2.5	3
16	Impact of Body Mass Index on Outcomes of Hematopoietic Stem Cell Transplantation in Adults. Biology of Blood and Marrow Transplantation, 2019, 25, 613-620.	2.0	31
17	Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy. Blood, 2019, 134, 413-413.	1.4	2
18	Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas. Blood, 2019, 134, 2889-2889.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 866-873.	4.5	33
20	CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. <i>Blood</i> , 2018, 131, 611-620.	1.4	49
21	Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma. <i>Blood Research</i> , 2018, 53, 223.	1.3	0
22	Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy. <i>Blood</i> , 2018, 132, 94-94.	1.4	10
23	Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody (90Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 1018-1018.	1.4	6
24	Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 1681-1681.	1.4	1
25	Ixazomib in Previously Untreated Indolent B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 5326-5326.	1.4	1
26	Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival. <i>Blood</i> , 2018, 132, 281-281.	1.4	0
27	Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. <i>Cancer Research</i> , 2017, 77, 3885-3893.	0.9	31
28	Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia. <i>Blood</i> , 2017, 130, 1170-1172.	1.4	18
29	EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. <i>Lancet Haematology</i> , 2017, 4, e414-e423.	4.6	92
30	Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1509-1514.	2.0	33
31	A Phase I Trial of 90Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma. <i>Blood</i> , 2017, 130, 910-910.	1.4	5
32	CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. <i>Journal of Clinical Investigation</i> , 2016, 126, 2123-2138.	8.2	1,657
33	Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1319-1323.	2.0	27
34	Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1227-1233.	2.0	36
35	Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spots. <i>Blood</i> , 2016, 127, 2773-2774.	1.4	17
36	Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers. <i>Cancer Research</i> , 2016, 76, 6669-6679.	0.9	25

#	ARTICLE	IF	CITATIONS
37	Cord-Blood Transplantation in Patients with Minimal Residual Disease. <i>New England Journal of Medicine</i> , 2016, 375, 944-953.	27.0	352
38	Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma. <i>Cancer Medicine</i> , 2015, 4, 1161-1170.	2.8	59
39	Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. <i>Blood</i> , 2015, 125, 2111-2119.	1.4	52
40	High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 788-797.	2.5	11
41	Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease. <i>British Journal of Haematology</i> , 2015, 171, 411-416.	2.5	9
42	The use of stereotactic radiosurgery for brain metastases from breast cancer: Who benefits most?. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 743-749.	2.5	26
43	Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1565-1575.	2.0	20
44	Employee influenza vaccination in a large cancer center with high baseline compliance rates: Comparison of carrot versus stick approaches. <i>American Journal of Infection Control</i> , 2015, 43, 228-233.	2.3	24
45	Estimating GFR in Adult Patients with Hematopoietic Cell Transplant. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 601-610.	4.5	34
46	High HLA-DP Expression and Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2015, 373, 599-609.	27.0	264
47	Urinary Elafin and Kidney Injury in Hematopoietic Cell Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 12-20.	4.5	28
48	Pre-Transplant Expressions of Micrnas Are Associated with Both Comorbidity Burden and Mortality Risks in Patients (Pts) with Acute Leukemia (AL) in Complete Remission (CR) Given Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2015, 126, 385-385.	1.4	3
49	A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 5502-5502.	1.4	0
50	Post-Hematopoietic Stem Cell Transplantation Minimal Residual Disease and Early Relapses in MDS and AML Evolving from MDS. <i>Blood</i> , 2015, 126, 2019-2019.	1.4	0
51	Regression of Metastatic Merkel Cell Carcinoma Following Transfer of Polyomavirus-Specific T Cells and Therapies Capable of Reinducing HLA Class-I. <i>Cancer Immunology Research</i> , 2014, 2, 27-36.	3.4	89
52	A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies. <i>Cancer Research</i> , 2014, 74, 1179-1189.	0.9	45
53	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. <i>Blood</i> , 2014, 124, 287-295.	1.4	83
54	Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 3967-3967.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Correlation of Infused CD3+CD8+ Cells with Single-Donor Dominance after Double-Unit Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 156-160.	2.0	28
56	Proliferation-Linked Apoptosis of Adoptively Transferred T Cells after IL-15 Administration in Macaques. <i>PLoS ONE</i> , 2013, 8, e56268.	2.5	4
57	A Phase I Study Of Myeloablative Radioimmunotherapy Using Iodine-131 Anti-CD45 Antibody Followed By Autologous Stem Cell Transplantation For High-Risk B-Cell and T-Cell Non-Hodgkin Lymphoma and Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 3333-3333.	1.4	2
58	Anti-CD38 Pretargeted Radioimmunotherapy Eradicates Multiple Myeloma Xenografts In a Murine Model. <i>Blood</i> , 2013, 122, 882-882.	1.4	2
59	Bendamustine (Treanda®)-Based Regimens Are Effective In Mobilizing Peripheral Blood Hematopoietic Stem Cells For Autologous Transplantation. <i>Blood</i> , 2013, 122, 2033-2033.	1.4	0
60	131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma. <i>Nuclear Medicine Communications</i> , 2012, 33, 1225-1231.	1.1	3
61	MHC-Resident Variation Affects Risks After Unrelated Donor Hematopoietic Cell Transplantation. <i>Science Translational Medicine</i> , 2012, 4, 144ra101.	12.4	55
62	Bendamustine (Treanda®), Etoposide and Dexamethasone (BED) Followed by GCSF Effectively Mobilizes Autologous Peripheral Blood Hematopoietic Stem Cells. <i>Blood</i> , 2012, 120, 4126-4126.	1.4	1
63	Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignancies Is Comparable to Unrelated Donor Transplantation: A Retrospective Single-Center Study. <i>Blood</i> , 2012, 120, 1995-1995.	1.4	0
64	A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1308-1315.	2.0	17
65	Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. <i>British Journal of Haematology</i> , 2011, 153, 76-82.	2.5	51
66	Anti-CD38 Pretargeted Radioimmunotherapy Demonstrates Therapeutic Efficacy In a Human Multiple Myeloma Mouse Xenograft Model. <i>Blood</i> , 2011, 118, 1842-1842.	1.4	1
67	Influence of Infused Naïve CD3+CD8+ and CD3+CD56+ NKT-Cells on Single Unit Dominance After Double Cord Blood Transplantation. <i>Blood</i> , 2011, 118, 652-652.	1.4	1
68	Impact of the Novel 5-Group Cytogenetic Risk Classification of MDS on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2011, 118, 666-666.	1.4	3
69	HLA mismatches and hematopoietic cell transplantation: structural simulations assess the impact of changes in pep-tide binding specificity on transplant outcome. <i>Immunome Research</i> , 2011, 7, 4.	0.1	9
70	Conventional Anti-CD45 Radioimmunotherapy Comparing 90Y or 177Lu for Treatment of AML in a Syngeneic Disseminated Murine Leukemia Model. <i>Blood</i> , 2011, 118, 3636-3636.	1.4	0
71	Umbilical Cord Blood Transplantation in Patients with Hematological Malignancies Using a Non-ATG Containing Reduced Intensity Preparative Regimen. <i>Blood</i> , 2011, 118, 1943-1943.	1.4	3
72	Characterization of Chronic Graft-Versus-Host Disease and Duration of Immunosuppression After Cord Blood Transplantation. <i>Blood</i> , 2011, 118, 4077-4077.	1.4	0

#	ARTICLE	IF	CITATIONS
73	A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma. <i>Blood</i> , 2011, 118, 663-663.	1.4	2
74	Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. <i>British Journal of Haematology</i> , 2010, 150, 170-178.	2.5	44
75	Re: An Approach to Predicting HSCT Outcome Using HLA-Mismatch Information Mapped on Protein Structure Data. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 865-866.	2.0	0
76	Tumor Necrosis Factor Polymorphism Affects Transplantation Outcome in Patients with Myelodysplastic Syndrome but Not in Those with Chronic Myelogenous Leukemia, Independent of the Presence of HLA-DR15. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1700-1706.	2.0	15
77	Differential Gene Expression Associated with Chronic Myeloid Leukemia (CML) Progression Predicts Relapse and Survival Prior to Allogeneic Transplantation In Chronic Phase CML Patients. <i>Blood</i> , 2010, 116, 3507-3507.	1.4	1
78	Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma. <i>Blood</i> , 2010, 116, 525-525.	1.4	2
79	Effect of Peripheral Blood Stem Cell (PBSC) Graft Composition on Graft Versus Host Disease (GVHD) and Mortality After Allogeneic Transplantation. <i>Blood</i> , 2010, 116, 676-676.	1.4	2
80	Pulse High-Dose Vorinostat Can Be Delivered with Rituximab, Ifosphamide, Carboplatin, and Etoposide In Patients with Relapsed Lymphoma: Final Results of a Phase I Trial.. <i>Blood</i> , 2010, 116, 2790-2790.	1.4	0
81	Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. <i>Journal of Experimental Medicine</i> , 2009, 206, 793-805.	8.5	105
82	Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4685-4692.	1.6	277
83	No telomere shortening in marrow stroma from patients with MDS. <i>Annals of Hematology</i> , 2009, 88, 623-628.	1.8	12
84	What Is the Role for Donor Natural Killer Cells after Nonmyeloablative Conditioning?. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 580-588.	2.0	52
85	Allogeneic hematopoietic cell transplantation after conditioning with 131I anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Blood</i> , 2009, 114, 5444-5453.	1.4	161
86	A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. <i>Blood</i> , 2009, 113, 4903-4913.	1.4	50
87	Are Neurology Residents Prepared to Deal With Dying Patients?. <i>Archives of Neurology</i> , 2009, 66, 1427-8.	4.5	34
88	A Phase I Study of Vorinostat (V) in Combination with Rituximab (R), Ifosphamide, Carboplatin, and Etoposide (ICE) for Patients with Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma.. <i>Blood</i> , 2009, 114, 3696-3696.	1.4	1
89	Reduced Relapse and Similar Progression-Free Survival After Double Umbilical Cord Blood Transplantation (DUCBT): Comparison of Outcomes Between Sibling, Unrelated Adult and Unrelated DUCB Hematopoietic Stem Cell (HSC) Donors.. <i>Blood</i> , 2009, 114, 662-662.	1.4	5
90	Outcomes of Early Relapse Following Non-Myeloablative Allogeneic Transplant for Lymphoma.. <i>Blood</i> , 2009, 114, 1204-1204.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Nonmyeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. <i>British Journal of Haematology</i> , 2008, 143, 395-403.	2.5	97
92	High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1899-1906.	1.3	23
93	Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1062-1073.	1.3	43
94	Preferentially Expressed Antigen in Melanoma (PRAME) Expression in Normal and CML CD34+ Progenitor Cells Impairs Myeloid Differentiation.. <i>Blood</i> , 2008, 112, 1071-1071.	1.4	1
95	Impact of Pre-Transplant Minimal Residual Disease Assessed by Flow Cytometry on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with AML-CR1.. <i>Blood</i> , 2008, 112, 3253-3253.	1.4	4
96	Genetic Allelic Variation in the p53 DNA Repair Pathway Constitute a Risk Factor for Long-Term Survival in Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 337-337.	1.4	1
97	A Prospective Multicenter Phase II Study by the Puget Sound Oncology Consortium (PSOC) of Gemcitabine (G), Carboplatin (C), Dexamethasone (D), and Rituximab (R) in Patients with Relapsed/Refractory Lymphoma. <i>Blood</i> , 2008, 112, 2585-2585.	1.4	0
98	Gene expression patterns in myelodysplasia underline the role of apoptosis and differentiation in disease initiation and progression. <i>Translational Oncogenomics</i> , 2008, 3, 137-49.	1.7	13
99	A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. <i>Blood</i> , 2007, 109, 4557-4563.	1.4	115
100	Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. <i>Blood</i> , 2007, 109, 2791-2793.	1.4	210
101	The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. <i>Blood</i> , 2007, 109, 1782-1789.	1.4	126
102	Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 355-365.	2.0	174
103	Cyclophosphamide following Targeted Oral Busulfan as Conditioning for Hematopoietic Cell Transplantation: Pharmacokinetics, Liver Toxicity, and Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 853-862.	2.0	89
104	Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. <i>Clinical Immunology</i> , 2007, 125, 275-280.	3.2	20
105	Outcome Following Hematopoietic Cell Transplantation for Patients with AML-CR1: Comparison between Matched-Sibling and Unrelated Allografts.. <i>Blood</i> , 2007, 110, 330-330.	1.4	4
106	What Is the Role for Donor NK Cells after Nonmyeloablative Conditioning?. <i>Blood</i> , 2007, 110, 476-476.	1.4	2
107	Higher Doses of Transplanted T and B Cells Are Associated with Greater Incidence of Extensive Chronic GVHD after PBSC Transplantation from HLA-Identical Sibling Donors.. <i>Blood</i> , 2007, 110, 1077-1077.	1.4	2
108	Outcomes after Autologous Stem Cell Transplantation for Mantle Cell Lymphoma Based on Remission Status and Induction Chemotherapy Regimen.. <i>Blood</i> , 2007, 110, 1905-1905.	1.4	0

#	ARTICLE	IF	CITATIONS
109	KIR Ligands and Prediction of Relapse after Unrelated Donor Hematopoietic Cell Transplantation for Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 828-836.	2.0	201
110	131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. <i>Blood</i> , 2006, 107, 2184-2191.	1.4	146
111	Favorable Outcome of Patients with Relapsed Hodgkin Lymphoma (HL) after Nonmyeloablative Hematopoietic Cell Transplantation (NM-HCT) Using Related Haploidentical Donors.. <i>Blood</i> , 2006, 108, 3135-3135.	1.4	9
112	Four-Year Follow-Up after High-Dose Immunosuppressive Therapy (HDIT) for Severe Systemic Sclerosis (SSc).. <i>Blood</i> , 2006, 108, 3071-3071.	1.4	0
113	Ablative Allogeneic Hematopoietic Cell Transplantation in Adults 60 Years of Age and Older. <i>Journal of Clinical Oncology</i> , 2005, 23, 3439-3446.	1.6	120
114	Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 713-720.	2.0	70
115	131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).. <i>Blood</i> , 2005, 106, 397-397.	1.4	19
116	Methylenetetrahydrofolate Reductase Genotype Affects Risk of Relapse after Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2004, 10, 7592-7598.	7.0	42
117	Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 552-560.	2.0	59
118	ADENOVIRUS NEPHRITIS IN HEMATOPOIETIC STEM-CELL TRANSPLANTATION. <i>Transplantation</i> , 2004, 77, 1049-1057.	1.0	89
119	Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. <i>Blood</i> , 2004, 103, 347-352.	1.4	225
120	Respiratory Syncytial Virus (RSV) Infection in Hematopoietic Stem Cell Transplant (HCT) Recipients: Risk Factors for Acquisition and Lower Respiratory Tract Disease, and Impact on Mortality.. <i>Blood</i> , 2004, 104, 187-187.	1.4	7
121	131I-Anti-CD45 Antibody Plus Busulfan/Cyclophosphamide in Matched Related Transplants for Acute Myeloid Leukemia in First Remission.. <i>Blood</i> , 2004, 104, 813-813.	1.4	2
122	A Retrospective Study of Patients Treated with Imatinib Mesylate Prior to Allogeneic Hematopoietic Stem Cell Transplant.. <i>Blood</i> , 2004, 104, 2752-2752.	1.4	113
123	The Follicular Lymphoma International Prognostic Index (FLIPI) as Part of a Proposed Prognostic Model for Follicular Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation (ASCT).. <i>Blood</i> , 2004, 104, 12-12.	1.4	0
124	Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML.. <i>Blood</i> , 2004, 104, 2316-2316.	1.4	1
125	Relation of an Interleukin-10 Promoter Polymorphism to Graft-versus-Host Disease and Survival after Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2003, 349, 2201-2210.	27.0	360
126	Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2003, 120, 281-288.	2.5	90

#	ARTICLE	IF	CITATIONS
127	Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 266-272.	2.0	31
128	Allogeneic hematopoietic stem cell transplantation for myelofibrosis. <i>Blood</i> , 2003, 102, 3912-3918.	1.4	255
129	Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. <i>Blood</i> , 2003, 101, 2043-2048.	1.4	323
130	Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. <i>Blood</i> , 2003, 101, 4195-4200.	1.4	214
131	High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. <i>Blood</i> , 2003, 102, 2351-2357.	1.4	187
132	HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. <i>Blood</i> , 2003, 102, 31-35.	1.4	168
133	High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. <i>Blood</i> , 2003, 102, 2364-2372.	1.4	219
134	Predictors of relapse and overall survival in Philadelphia chromosome[ndash]positive acute lymphoblastic leukemia after transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 206-212.	2.0	64
135	Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. <i>Clinical Cancer Research</i> , 2003, 9, 5559-65.	7.0	62
136	Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide-Based Vaccines. <i>Journal of Clinical Oncology</i> , 2002, 20, 2624-2632.	1.6	411
137	High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. <i>Blood</i> , 2002, 99, 3158-3162.	1.4	205
138	Curative Therapy of Advanced Essential Thrombocythemia or Polycythemia Vera by Hemopoietic Stem Cell Transplantation. <i>Leukemia and Lymphoma</i> , 2002, 43, 1409-1414.	1.3	19
139	Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. <i>Cancer</i> , 2002, 95, 1354-1365.	4.1	37
140	High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. <i>Blood</i> , 2002, 100, 1602-10.	1.4	61
141	Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 384-387.	2.0	98
142	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. <i>Blood</i> , 2001, 97, 3390-3400.	1.4	1,306
143	Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. <i>Blood</i> , 2001, 97, 2180-2181.	1.4	64
144	Absence of statistically significant correlation between disparity for the minor histocompatibility antigen HA-1 and outcome after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2001, 98, 3172-3173.	1.4	53

#	ARTICLE	IF	CITATIONS
145	Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. <i>Blood</i> , 2001, 98, 3584-3588.	1.4	101
146	Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. <i>Blood</i> , 2001, 98, 3868-3870.	1.4	64
147	Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. <i>Blood</i> , 2001, 98, 573-578.	1.4	284
148	Increased prevalence of CMV gB3 in marrow of patients with aplastic anemia. <i>Blood</i> , 2001, 98, 891-892.	1.4	10
149	The significance of bcr-abl molecular detection in chronic myeloid leukemia patients ≥18 months or more after transplantation. <i>Blood</i> , 2001, 98, 1701-1707.	1.4	137
150	The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2001, 112, 988-994.	2.5	134
151	Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. <i>British Journal of Haematology</i> , 2000, 110, 217-222.	2.5	39
152	Cutting Edge: Persistent Fetal Microchimerism in T Lymphocytes Is Associated with HLA-DQA1*0501: Implications in Autoimmunity. <i>Journal of Immunology</i> , 2000, 164, 5545-5548.	0.8	125
153	Negative Regulators of Hemopoiesis and Stroma Function in Patients with Myelodysplastic Syndrome. <i>Leukemia and Lymphoma</i> , 2000, 37, 405-414.	1.3	121
154	Second allogeneic transplantation after failure of first autologous transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 272-279.	2.0	89
155	Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 613-620.	2.0	48
156	A phase I/II trial of iodine-131 ¹²⁵ I-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. <i>Blood</i> , 2000, 96, 2934-2942.	1.4	258
157	Reply. <i>Journal of Infectious Diseases</i> , 1999, 180, 572-574.	4.0	1
158	Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: Incidence, risk factors, and outcome. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 306-315.	2.0	126
159	The Biologic Significance of Rare Peripheral Blasts After Hematopoietic Cell Transplantation Is Predicted by Multidimensional Flow Cytometry. <i>American Journal of Clinical Pathology</i> , 1999, 112, 513-523.	0.7	24
160	Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. <i>Lancet</i> , The, 1998, 351, 559-562.	13.7	574
161	Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 1998, 338, 962-968.	27.0	602
162	Optimizing Outcome After Unrelated Marrow Transplantation by Comprehensive Matching of HLA Class I and II Alleles in the Donor and Recipient. <i>Blood</i> , 1998, 92, 3515-3520.	1.4	442

#	ARTICLE	IF	CITATIONS
163	Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. American Journal of Hematology, 1997, 54, 131-138.	4.1	203
164	UTILITY OF TRANSVENOUS LIVER BIOPSIES AND WEDGED HEPATIC VENOUS PRESSURE MEASUREMENTS IN SIXTY MARROW TRANSPLANT RECIPIENTS. Transplantation, 1995, 59, 1015-1022.	1.0	144